secwatch.observer — SEC 8-K summary
======================================

Issuer:     PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB)
CIK:        0001299130
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001104659-24-115295
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PacBio Q3 revenue falls 28% to $40M; CFO resigns; notes exchange with SoftBank
------------------------------------------------------------------------------

- Revenue $40.0M (-28% YoY); instrument revenue $16.8M (down from $34.7M); 22 Revio systems shipped.
- Net loss $60.7M ($0.22/sh) vs $66.9M ($0.26) prior year; non-GAAP net loss $46.0M ($0.17).
- CFO Susan Kim resigns effective Dec 6; no severance; search for replacement underway.
- Announced $459M convertible note exchange (1.50% due 2028) with SoftBank, expected close Nov 21.
- Launched SPRQ chemistry increasing Revio throughput 33%; unveiled Vega benchtop sequencer at $169K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1299130/000110465924115295/0001104659-24-115295-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1299130/000110465924115295/tm2427787d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-115295

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer